How Wegovy reshapes prescription weight loss in the US

Wegovy is a prescription weight-loss injection that changed how US doctors treat obesity. Here is how it works, what to expect on treatment, and how it fits into long term care.

Wegovy is a once-weekly semaglutide injection for chronic weight management that received FDA approval for adults with obesity or overweight with at least one weight related condition in 06/2021 FDA, 06/04/2021Novo Nordisk, 06/04/2021.

Updated: 05/17/2026 | Reading time: approx. 11 minutes

By the AD HOC NEWS editorial team - specialized in product-led market coverage.

At a Glance

• Product: Wegovy
• Category: Prescription weight-loss medicine (GLP-1 receptor agonist)
• Brand/Manufacturer: Novo Nordisk
• Main Use Cases: Chronic weight management in adults with obesity or overweight plus weight related conditions
• Availability: Prescription only in the US with boxed warning and Risk Evaluation and Mitigation Strategy
• Key Markets: United States and other selected global markets where approved

What Wegovy Is and How It Works

Wegovy is a branded form of semaglutide, a GLP-1 receptor agonist specifically indicated for chronic weight management, not diabetes treatment, at a higher dose than diabetes focused semaglutide products FDA, 06/04/2021Novo Nordisk, 2024.

The medicine comes in single use, prefilled injection pens designed for once weekly self administration, usually in the abdomen, thigh, or upper arm, and is intended to be used together with a reduced calorie diet and increased physical activity Novo Nordisk, 2024FDA label, 12/2023.

Semaglutide acts on GLP-1 receptors in the brain and gut to help reduce appetite and increase feelings of fullness after eating, which can support lower calorie intake when combined with lifestyle changes, according to the prescribing information FDA label, 12/2023Novo Nordisk PI, 12/2023.

Dosing and titration schedule

Wegovy treatment usually starts at a low weekly dose that is increased gradually over several months so that the body can adjust and to help reduce side effects such as nausea and vomiting, according to the US prescribing information FDA label, 12/2023Novo Nordisk HCP, 2024.

The medication guide instructs patients to use the pen on the same day each week, with or without food, and notes that if a dose is missed and the next dose is more than 2 days away, the missed dose can often be taken, following doctor guidance Medication Guide, 12/2023FDA label, 12/2023.

Who Wegovy is approved for

In the US, Wegovy is approved for adults with a body mass index of at least 30 kg per square meter or at least 27 kg per square meter with at least one weight related condition such as high blood pressure, type 2 diabetes, or high cholesterol FDA, 06/04/2021FDA label, 12/2023.

The FDA has added an indication for reducing the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight, based on clinical trial data showing benefit when Wegovy is used with standard cardiovascular therapies FDA, 03/08/2024Novo Nordisk, 03/08/2024.

Why Wegovy Matters for Consumers and Industry

For individual patients, Wegovy offers a non surgical option for chronic weight management in combination with lifestyle changes, in an area where long term pharmacologic options have been limited in the past, according to the FDA obesity treatment overview FDA, 03/21/2022FDA label, 12/2023.

Randomized trials of semaglutide at the Wegovy dose in adults with obesity or overweight have shown clinically meaningful average weight loss compared with placebo when the medicine is used on top of a reduced calorie diet and increased physical activity NEJM, 02/10/2021JAMA, 01/05/2022.

The cardiovascular indication reflects trial results showing that once weekly semaglutide at the Wegovy dose reduced the relative risk of major adverse cardiovascular events versus placebo in adults with obesity and cardiovascular disease, on top of standard care NEJM, 03/06/2024FDA, 03/08/2024.

Safety profile and boxed warning

The US prescribing information carries a boxed warning about thyroid C cell tumors in rodent studies and states that Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma or in patients with MEN 2 FDA label, 12/2023FDA, 2024.

Common side effects reported in clinical trials include nausea, diarrhea, vomiting, constipation, and abdominal pain, and the medication guide advises patients to contact their health care provider if they experience severe stomach pain, vision changes, or symptoms of allergic reaction Medication Guide, 12/2023FDA, 03/21/2022.

Impact on clinical practice and patient experience

US obesity specialists cited by professional groups describe GLP-1 based medicines like Wegovy as one tool among others, where long term success still depends on nutrition, physical activity, sleep, and behavioral support alongside medication use Endocrine Society, 06/2023Obesity Society, 2024.

Clinics in the US report that patients often value the once weekly schedule and the potential to combine weight management and cardiometabolic risk reduction, while also needing careful counseling on side effects, cost, and realistic expectations for long term maintenance Cleveland Clinic, 01/2024Mayo Clinic, 2023.

Wegovy in the US and Global Market

In the United States, Wegovy is available only by prescription, and the FDA requires a Risk Evaluation and Mitigation Strategy that includes a medication guide and communication plan for health care providers to help manage risks such as thyroid tumors and pancreatitis FDA, 2024Wegovy REMS, 10/24/2023.

US media and analysts note that demand for GLP-1 weight loss medicines, including Wegovy, has been high, contributing to intermittent supply constraints and prompting manufacturers to expand production capacity for these injectable products Reuters, 11/02/2023Wall Street Journal, 10/29/2023.

Outside the United States, Wegovy has been introduced in selected markets following local regulatory reviews, and Novo Nordisk has stated that rollouts are staged to balance supply with demand for obesity and diabetes uses of semaglutide in different regions Novo Nordisk, 08/10/2023Financial Times, 09/01/2023.

Competition and insurance coverage

In the US, Wegovy competes with other GLP-1 and related weight management medicines, including Eli Lillys tirzepatide injection for chronic weight management, which received FDA approval with its own set of indications and safety information FDA, 11/08/2023Eli Lilly, 11/08/2023.

US coverage for Wegovy varies, with some commercial plans and employer programs providing benefits, while coverage under Medicare and Medicaid has been more limited for weight loss indications; policy discussions about obesity drug coverage have been ongoing in Congress and among payers KFF, 02/22/2024NBC News, 03/08/2024.

• Once weekly injection designed for chronic weight management in adults with obesity or overweight.
• Works on GLP-1 receptors to help reduce appetite and support lower calorie intake.
• Requires prescription, lifestyle changes, and medical monitoring of side effects and long term risks.

Frequently Asked Questions About Wegovy

Is Wegovy approved in the US?
Yes. The FDA approved Wegovy in 06/2021 for chronic weight management in certain adults with obesity or overweight plus at least one weight related condition FDA, 06/04/2021.

Do I still need diet and exercise on Wegovy?
Yes. The US label states that Wegovy is indicated as an adjunct to a reduced calorie diet and increased physical activity, so lifestyle changes remain part of treatment FDA label, 12/2023.

Can Wegovy be used if I have diabetes?
The prescribing information notes that Wegovy is not indicated for treatment of type 2 diabetes, though some people with obesity and type 2 diabetes were included in trials; individual use should be guided by a health care provider FDA label, 12/2023.

Wegovy is developed and marketed by Novo Nordisk, a Denmark based pharmaceutical group focused on therapies for serious chronic diseases including diabetes and obesity.

Shares of Novo Nordisk A/S trade in the US as an American depositary receipt under the ticker NVO, and the issuer has the international securities identification number DK0060534915.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.